全文获取类型
收费全文 | 11888篇 |
免费 | 830篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 77篇 |
儿科学 | 365篇 |
妇产科学 | 347篇 |
基础医学 | 1664篇 |
口腔科学 | 185篇 |
临床医学 | 1368篇 |
内科学 | 2455篇 |
皮肤病学 | 277篇 |
神经病学 | 1356篇 |
特种医学 | 379篇 |
外科学 | 1068篇 |
综合类 | 95篇 |
一般理论 | 1篇 |
预防医学 | 1020篇 |
眼科学 | 363篇 |
药学 | 662篇 |
中国医学 | 26篇 |
肿瘤学 | 1067篇 |
出版年
2024年 | 15篇 |
2023年 | 135篇 |
2022年 | 222篇 |
2021年 | 455篇 |
2020年 | 294篇 |
2019年 | 420篇 |
2018年 | 395篇 |
2017年 | 315篇 |
2016年 | 362篇 |
2015年 | 372篇 |
2014年 | 485篇 |
2013年 | 694篇 |
2012年 | 993篇 |
2011年 | 1009篇 |
2010年 | 528篇 |
2009年 | 432篇 |
2008年 | 763篇 |
2007年 | 794篇 |
2006年 | 691篇 |
2005年 | 593篇 |
2004年 | 597篇 |
2003年 | 531篇 |
2002年 | 532篇 |
2001年 | 62篇 |
2000年 | 54篇 |
1999年 | 83篇 |
1998年 | 93篇 |
1997年 | 67篇 |
1996年 | 54篇 |
1995年 | 45篇 |
1994年 | 48篇 |
1993年 | 44篇 |
1992年 | 39篇 |
1991年 | 44篇 |
1990年 | 20篇 |
1989年 | 26篇 |
1988年 | 21篇 |
1987年 | 27篇 |
1985年 | 26篇 |
1984年 | 28篇 |
1983年 | 20篇 |
1982年 | 31篇 |
1981年 | 32篇 |
1980年 | 32篇 |
1979年 | 19篇 |
1978年 | 23篇 |
1977年 | 17篇 |
1976年 | 16篇 |
1975年 | 16篇 |
1974年 | 17篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
971.
972.
973.
974.
Petros Ioannou Aggeliki Andrianaki Tonia Akoumianaki Irene Kyrmizi Nathaniel Albert David Perlin George Samonis Dimitrios P. Kontoyiannis Georgios Chamilos 《Antimicrobial agents and chemotherapy》2016,60(3):1226-1233
The modest in vitro activity of echinocandins against Aspergillus implies that host-related factors augment the action of these antifungal agents in vivo. We found that, in contrast to the other antifungal agents (voriconazole, amphotericin B) tested, caspofungin exhibited a profound increase in activity against various Aspergillus species under conditions of cell culture growth, as evidenced by a ≥4-fold decrease in minimum effective concentrations (MECs) (P = 0. 0005). Importantly, the enhanced activity of caspofungin against Aspergillus spp. under cell culture conditions was strictly dependent on serum albumin and was not observed with the other two echinocandins, micafungin and anidulafungin. Of interest, fluorescently labeled albumin bound preferentially on the surface of germinating Aspergillus hyphae, and this interaction was further enhanced upon treatment with caspofungin. In addition, supplementation of cell culture medium with albumin resulted in a significant, 5-fold increase in association of fluorescently labeled caspofungin with Aspergillus hyphae (P < 0.0001). Collectively, we found a novel synergistic interaction between albumin and caspofungin, with albumin acting as a potential carrier molecule to facilitate antifungal drug delivery to Aspergillus hyphae. 相似文献
975.
Ana B. Sanchez Giuseppe P. Varano Cyrus M. de Rozieres Ricky Maung Irene C. Catalan Cari C. Dowling Natalia E. Sejbuk Melanie M. Hoefer Marcus Kaul 《Antimicrobial agents and chemotherapy》2016,60(1):168-179
HIV-1 infection frequently causes HIV-associated neurocognitive disorders (HAND) despite combination antiretroviral therapy (cART). Evidence is accumulating that components of cART can themselves be neurotoxic upon long-term exposure. In addition, abuse of psychostimulants, such as methamphetamine, seems to aggravate HAND and compromise antiretroviral therapy. However, the combined effect of virus and recreational and therapeutic drugs on the brain is poorly understood. Therefore, we exposed mixed neuronal-glial cerebrocortical cells to antiretrovirals (ARVs) (zidovudine [AZT], nevirapine [NVP], saquinavir [SQV], and 118-D-24) of four different pharmacological categories and to methamphetamine and, in some experiments, the HIV-1 gp120 protein for 24 h and 7 days. Subsequently, we assessed neuronal injury by fluorescence microscopy, using specific markers for neuronal dendrites and presynaptic terminals. We also analyzed the disturbance of neuronal ATP levels and assessed the involvement of autophagy by using immunofluorescence and Western blotting. ARVs caused alterations of neurites and presynaptic terminals primarily during the 7-day incubation and depending on the specific compounds and their combinations with and without methamphetamine. Similarly, the loss of neuronal ATP was context specific for each of the drugs or combinations thereof, with and without methamphetamine or viral gp120. Loss of ATP was associated with activation of AMP-activated protein kinase (AMPK) and autophagy, which, however, failed to restore normal levels of neuronal ATP. In contrast, boosting autophagy with rapamycin prevented the long-term drop of ATP during exposure to cART in combination with methamphetamine or gp120. Our findings indicate that the overall positive effect of cART on HIV infection is accompanied by detectable neurotoxicity, which in turn may be aggravated by methamphetamine. 相似文献
976.
Koh Y Nakata H Maeda K Ogata H Bilcer G Devasamudram T Kincaid JF Boross P Wang YF Tie Y Volarath P Gaddis L Harrison RW Weber IT Ghosh AK Mitsuya H 《Antimicrobial agents and chemotherapy》2003,47(10):3123-3129
We designed, synthesized, and identified UIC-94017 (TMC114), a novel nonpeptidic human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) containing a 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane (bis-THF) and a sulfonamide isostere which is extremely potent against laboratory HIV-1 strains and primary clinical isolates (50% inhibitory concentration [IC(50)], approximately 0.003 micro M; IC(90), approximately 0.009 micro M) with minimal cytotoxicity (50% cytotoxic concentration for CD4(+) MT-2 cells, 74 micro M). UIC-94017 blocked the infectivity and replication of each of HIV-1(NL4-3) variants exposed to and selected for resistance to saquinavir, indinavir, nelfinavir, or ritonavir at concentrations up to 5 micro M (IC(50)s, 0.003 to 0.029 micro M), although it was less active against HIV-1(NL4-3) variants selected for resistance to amprenavir (IC(50), 0.22 micro M). UIC-94017 was also potent against multi-PI-resistant clinical HIV-1 variants isolated from patients who had no response to existing antiviral regimens after having received a variety of antiviral agents. Structural analyses revealed that the close contact of UIC-94017 with the main chains of the protease active-site amino acids (Asp-29 and Asp-30) is important for its potency and wide spectrum of activity against multi-PI-resistant HIV-1 variants. Considering the favorable pharmacokinetics of UIC-94017 when administered with ritonavir, the present data warrant that UIC-94017 be further developed as a potential therapeutic agent for the treatment of primary and multi-PI-resistant HIV-1 infections. 相似文献
977.
Kelvin L. Chou Melissa M. Amick Jason Brandt Richard Camicioli Karen Frei Darren Gitelman Jennifer Goldman John Growdon Howard I. Hurtig Bonnie Levin Irene Litvan Laura Marsh Tanya Simuni Alexander I. Trster Ergun Y. Uc 《Movement disorders》2010,25(15):2501-2507
Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to make recommendations for a cognitive scale that could screen for dementia and mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome. This Task Force conducted a systematic literature search for cognitive assessments previously used in a PD population. Scales were then evaluated for their appropriateness to screen for cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment of the major cognitive domains, and potential to detect subtle cognitive impairment in PD. Five scales of global cognition met the predetermined screening criteria and were considered for review. Based on the Task Force's evaluation criteria the Montreal Cognitive Assessment (MoCA), appeared to be the most suitable measure. This Task Force recommends consideration of the MoCA as a minimum cognitive screening measure in clinical trials of PD where cognitive performance is not the primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD populations but appears to be the most appropriate measure among the currently available brief cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical trials can improve comparability between research studies on PD. © 2010 Movement Disorder Society 相似文献
978.
Roser Pons Mercedes Serrano Aida Ormazabal Claudio Toma Angels Garcia‐Cazorla Estela Area Marta Ribass Emmanuel Kanavakis Kaliopi Drakaki Aristotelis Giannakopoulos Irene Orfanou Sotiris Youroukos Bru Cormand Rafael Artuch 《Movement disorders》2010,25(8):1086-1090
We present the clinical, biochemical, and molecular findings of three Greek patients with tyrosine hydroxylase (TH) deficiency. All patients presented with a severe clinical phenotype characterized by prominent motor delay, infantile parkinsonism, oculogyric crises, and signs of autonomic dysfunction. Cerebrospinal fluid analysis disclosed reduced dopamine metabolites and normal pterins. Response to levodopa was favorable though not dramatic. All patients were homozygous for a previously reported mutation (p.L236P). SNP haplotype analysis was consistent with a common ancestral mutation, thus indicating a founder effect in Greek patients with TH deficiency. © 2010 Movement Disorder Society 相似文献
979.
980.
Joanna M. Dragich Dawn H. Loh Louisa M. Wang Andrew M. Vosko Takashi Kudo Takahiro J. Nakamura Irene H. Odom Sei Tateyama Arkady Hagopian James A. Waschek Christopher S. Colwell 《The European journal of neuroscience》2010,31(5):864-875
Previously, we have shown that mice deficient in either vasoactive intestinal peptide (VIP) or pituitary adenylate cyclase‐activating polypeptide (PACAP) exhibit specific deficits in the behavioral response of their circadian system to light. In this study, we investigated how the photic regulation of the molecular clock within the suprachiasmatic nucleus (SCN) is altered by the loss of these closely‐related peptides. During the subjective night, the magnitude of the light‐induction of FOS and phosphorylated mitogen‐activated protein kinase (p‐MAPK) immunoreactive cells within the SCN was significantly reduced in both VIP‐ and PACAP‐deficient mice when compared with wild‐type mice. The photic induction of the clock gene Period1 (Per1) in the SCN was reduced in the VIP‐ but not in the PACAP‐deficient mice. Baselines levels of FOS, p‐MAPK or Per1 in the night were not altered by the loss of these peptides. In contrast, during the subjective day, light exposure increased the levels of FOS, p‐MAPK and Per1 in the SCN of VIP‐deficient mice, but not in the other genotypes. During this phase, baseline levels of these markers were reduced in the VIP‐deficient mice compared with untreated controls. Finally, the loss of either neuropeptide reduced the magnitude of the light‐evoked increase in Per1 levels in the adrenals in the subjective night without any change in baseline levels. In summary, our results indicate that both VIP and PACAP regulate the responsiveness of cells within the SCN to the effects of light. Furthermore, VIP, but not PACAP, is required for the appropriate temporal gating of light‐induced gene expression within the SCN. 相似文献